The SIGNAL Trial: Steroids in ImmunoGlobulin A Nephropathy: Assessment of Long term outcomes

SIGNAL 试验：类固醇治疗免疫球蛋白 A 肾病：长期结果评估

• 批准号: nhmrc : 1042474
• 负责人: A/Pr Meg Jardine
• 金额: $ 186.98万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/signal-trial-steroids-term-outcomes/111471
• 关键词: SIGNAL; Trial; Steroids; ImmunoGlobulin; Nephropathy

IgA nephropathy is one of the most common causes of kidney failure in Australia and around the world, but there are currently no specific treatments proven to prevent kidney failure. The SIGNAL trial, jointly led by Australian and Chinese researchers, will bring together leading experts from around the world to reliably ascertain the effects of steroid therapy in this condition, and could potentially prevent many people from developing kidney failure in the future.

IGA肾病是澳大利亚和世界各地最常见的肾衰竭原因之一，但目前还没有被证明可以预防肾衰竭的具体治疗方法。Signal试验由澳大利亚和中国的研究人员联合领导，将汇集来自世界各地的顶尖专家，可靠地确定类固醇治疗在这种情况下的效果，并有可能防止许多人在未来发展为肾衰竭。